{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:19:57Z","timestamp":1784204397968,"version":"3.55.0"},"reference-count":124,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T00:00:00Z","timestamp":1607212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer that predominantly arises in chronically sun-damaged skin. Immunosuppression, genetic disorders such as xeroderma pigmentosum (XP), exposure to certain drugs and environmental noxae have been identified as major risk factors. Surgical removal of cSCC is the therapy of choice and mostly curative in early stages. However, a minority of patients develop locally advanced tumors or distant metastases that are still challenging to treat. Immune checkpoint blockade (ICB) targeting CTLA-4, PD-L1 and PD-1 has tremendously changed the field of oncological therapy and especially the treatment of skin cancers as tumors with a high mutational burden. In this review, we focus on the differences between cSCC and cutaneous melanoma (CM) and their implications on therapy, summarize the current evidence on ICB for the treatment of advanced cSCC and discuss the chances and pitfalls of this therapy option for this cancer entity. Furthermore, we focus on special subgroups of interest such as organ transplant recipients, patients with hematologic malignancies, XP and field cancerization.<\/jats:p>","DOI":"10.3390\/ijms21239300","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T12:24:39Z","timestamp":1607343879000},"page":"9300","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1940-5115","authenticated-orcid":false,"given":"Anja","family":"Wessely","sequence":"first","affiliation":[{"name":"Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9008-0088","authenticated-orcid":false,"given":"Theresa","family":"Steeb","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Eberhard Karls University of T\u00fcbingen, 72074 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Eberhard Karls University of T\u00fcbingen, 72074 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-1825","authenticated-orcid":false,"given":"Markus Vincent","family":"Heppt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-University Erlangen-N\u00fcrnberg (FAU), 91054 Erlangen, Germany"},{"name":"Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1365-2133.2012.10830.x","article-title":"A systematic review of worldwide incidence of nonmelanoma skin cancer","volume":"166","author":"Lomas","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41568-018-0024-5","article-title":"Deciphering the cells of origin of squamous cell carcinomas","volume":"18","author":"Blanpain","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial","volume":"115","author":"Criscione","year":"2009","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/bjd.12420","article-title":"The natural history of actinic keratosis: A systematic review","volume":"169","author":"Werner","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2340\/00015555-2692","article-title":"Actinic Keratosis, a Chronic, Progressive Disease: Understanding Clinical Gaps to Optimise Patient Management","volume":"97","author":"Cerio","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bjd.15324","article-title":"Cutaneous squamous cell carcinoma: An epidemiological review","volume":"177","author":"Green","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.mayocp.2017.02.015","article-title":"Incidence and Trends of Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma: A Population-Based Study in Olmsted County, Minnesota, 2000 to 2010","volume":"92","author":"Muzic","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jdv.15967","article-title":"Incidence and mortality for cutaneous squamous cell carcinoma: Comparison across three continents","volume":"33","author":"Stang","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamadermatol.2014.762","article-title":"Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978\u20132012: Empirical relationships","volume":"150","author":"Xiang","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-0-387-77574-6_8","article-title":"Epidemiology of melanoma and nonmelanoma skin cancer\u2014The role of sunlight","volume":"624","author":"Leiter","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jamadermatol.2016.4070","article-title":"Anatomical Distributions of Basal Cell Carcinoma and Squamous Cell Carcinoma in a Population-Based Study in Queensland, Australia","volume":"153","author":"Subramaniam","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/ajt.14382","article-title":"Skin Cancers in Organ Transplant Recipients","volume":"17","author":"Mittal","year":"2017","journal-title":"Am. J. Transpl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/jnci\/djs529","article-title":"HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer","volume":"105","author":"Silverberg","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/jamadermatol.2013.6249","article-title":"Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia","volume":"150","author":"Velez","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaad.2014.10.028","article-title":"Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: A Rochester Epidemiology Project population-based study in Minnesota","volume":"72","author":"Brewer","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1210\/en.2017-03230","article-title":"How UV Light Touches the Brain and Endocrine System through Skin, and Why","volume":"159","author":"Slominski","year":"2018","journal-title":"Endocrinology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.jidsp.5640173","article-title":"Ultraviolet radiation induced signature mutations in photocarcinogenesis","volume":"4","author":"Wikonkal","year":"1999","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0027-5107(98)00185-7","article-title":"UVA-induced immunosuppression","volume":"422","author":"Halliday","year":"1998","journal-title":"Mutat. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2340\/00015555-3123","article-title":"Skin Cancer Associated Genodermatoses: A Literature Review","volume":"99","author":"Schierbeck","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased Risk of Cutaneous Squamous Cell Carcinoma after Vismodegib Therapy for Basal Cell Carcinoma","volume":"152","author":"Mohan","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"83280","DOI":"10.18632\/oncotarget.21059","article-title":"Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF\/MEK inhibitors in cancer patients: A meta-analysis","volume":"8","author":"Peng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_22","unstructured":"European Medicines Agency (EMA) (2020, October 19). EMA Review of Picato Concludes Medicine\u2019s Risks Outweigh Its Benefits, Available online: https:\/\/www.ema.europa.eu\/en\/news\/ema-review-picato-concludes-medicines-risks-outweigh-its-benefits."},{"key":"ref_23","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) (2020, October 26). Rote-Hand-Brief zu Picato\u00ae (Ingenolmebutat): Vorsicht bei der Behandlung von Patienten mit Hautkrebsanamnese. Available online: https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2019\/rhb-picato.pdf?__blob=publicationFile&v=7."},{"key":"ref_24","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM) (2020, October 26). Rote-Hand-Brief zu Picato\u00ae (Ingenolmebutat)\u2014Ruhen der Zulassungen aufgrund des Risikos von malignen Hautver\u00e4nderungen. Available online: https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2020\/rhb-picato.pdf;jsessionid=767355ADF2B76F472CEC011BA27627F5.1_cid319?__blob=publicationFile&v=1."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jaad.2017.08.058","article-title":"Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors","volume":"78","author":"Que","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/archsurg.1989.01410010125024","article-title":"Squamous cell carcinoma arising in previously burned or irradiated skin","volume":"124","author":"Edwards","year":"1989","journal-title":"Arch. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/DSS.0000000000000478","article-title":"Consensus for Nonmelanoma Skin Cancer Treatment, Part II: Squamous Cell Carcinoma, Including a Cost Analysis of Treatment Methods","volume":"41","author":"Kauvar","year":"2015","journal-title":"Dermatol. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/jdv.16024","article-title":"Medical treatment of advanced cutaneous squamous-cell carcinoma","volume":"33","author":"Gellrich","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hed.22913","article-title":"Distant metastases from cutaneous squamous cell carcinoma\u2014Analysis of AJCC stage IV","volume":"35","author":"Brunner","year":"2013","journal-title":"Head Neck"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/jdv.16007","article-title":"Stage IV cutaneous squamous cell carcinoma (cSCC): Treatment outcomes in a series of 42 patients","volume":"34","author":"Chapalain","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","first-page":"CD011123","article-title":"Systemic treatments for metastatic cutaneous melanoma","volume":"2","author":"Pasquali","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejca.2016.12.041","article-title":"Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges","volume":"78","author":"Dumenil","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"104460","DOI":"10.1016\/j.oraloncology.2019.104460","article-title":"Immunotherapy for head and neck cancer: Recent advances and future directions","volume":"99","author":"Cramer","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.bbamcr.2013.06.010","article-title":"Cell death by cornification","volume":"1833","author":"Eckhart","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1083\/jcb.66.3.663","article-title":"Mitotic activity in non-neoplastic melanocytes in vivo as determined by histochemical, autoradiographic, and electron microscope studies","volume":"66","author":"Jimbow","year":"1975","journal-title":"J. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1755-148X.2009.00610.x","article-title":"Current challenges in understanding melanogenesis: Bridging chemistry, biological control, morphology, and function","volume":"22","author":"Simon","year":"2009","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"D\u2019Mello, S.A., Finlay, G.J., Baguley, B.C., and Askarian-Amiri, M.E. (2016). Signaling Pathways in Melanogenesis. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17071144"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1087-0024.2005.200407.x","article-title":"Normal human melanocyte homeostasis as a paradigm for understanding melanoma","volume":"10","author":"Haass","year":"2005","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nature05660","article-title":"Melanocyte biology and skin pigmentation","volume":"445","author":"Lin","year":"2007","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1152\/physrev.00044.2003","article-title":"Melanin pigmentation in mammalian skin and its hormonal regulation","volume":"84","author":"Slominski","year":"2004","journal-title":"Physiol. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1590\/S0365-05962013000100009","article-title":"Mechanisms regulating melanogenesis","volume":"88","author":"Videira","year":"2013","journal-title":"An. Bras. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.mrrev.2010.06.002","article-title":"Genetics of pigmentation in skin cancer\u2014A review","volume":"705","author":"Scherer","year":"2010","journal-title":"Mutat. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/er.2012-1092","article-title":"Key role of CRF in the skin stress response system","volume":"34","author":"Slominski","year":"2013","journal-title":"Endocr. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1152\/physrev.2000.80.3.979","article-title":"Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress","volume":"80","author":"Slominski","year":"2000","journal-title":"Physiol. Rev."},{"key":"ref_46","first-page":"457","article-title":"Neuroendocrinology of the skin","volume":"21","author":"Slominski","year":"2000","journal-title":"Endocr. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/php.12335","article-title":"MC1R, eumelanin and pheomelanin: Their role in determining the susceptibility to skin cancer","volume":"91","author":"Nasti","year":"2015","journal-title":"Photochem. Photobiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0190-9622(84)80305-9","article-title":"Physiologic skin changes in pregnancy","volume":"10","author":"Wong","year":"1984","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/15476278.2017.1421882","article-title":"Embryonic skin development and repair","volume":"14","author":"Hu","year":"2018","journal-title":"Organogenesis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1242\/dmm.023184","article-title":"Echoes of the embryo: Using the developmental biology toolkit to study cancer","volume":"9","author":"Aiello","year":"2016","journal-title":"Dis. Model Mech."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/emmm.201201862","article-title":"The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival","volume":"5","author":"Hohenauer","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jid.2017.05.038","article-title":"MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression","volume":"138","author":"Heppt","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_53","first-page":"120","article-title":"Epidemiology of skin cancer","volume":"810","author":"Leiter","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/CJI.0000000000000146","article-title":"Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy","volume":"40","author":"Day","year":"2017","journal-title":"J. Immunother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/bjd.14642","article-title":"Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: Preliminary experience in five cases","volume":"175","author":"Borradori","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Goldman, J.W., Abdalla, B., Mendenhall, M.A., Sisk, A., Hunt, J., Danovitch, G.M., and Lum, E.L. (2018). PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin\u2014Case report. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1003-5"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s40425-018-0444-5","article-title":"Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma","volume":"6","author":"Oliveira","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Fujimura, T., Kambayashi, Y., Tono, H., Lyu, C., Ohuchi, K., Hashimoto, A., and Aiba, S. (2020). Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy. Dermatol. Ther., e13672.","DOI":"10.1111\/dth.13672"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000505478","article-title":"Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma","volume":"12","author":"Florez","year":"2020","journal-title":"Case Rep. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Beasley, G.M., Kurtz, J., Vandeusen, J., Howard, J.H., Terando, A., Agnese, D., Liebner, D., Jeter, J., and Olencki, T. (2017). Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma. Clin. Skin Cancer, 05.","DOI":"10.1016\/j.clsc.2017.04.001"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1684\/ejd.2017.3209","article-title":"Nivolumab for recurrent cutaneous squamous cell carcinoma: Three cases","volume":"28","author":"Blum","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_64","unstructured":"Ferrarotto, R., Glisson, B., Blumenschein, G., Hong, D., Piha-Paul, S., Jain, D., Alshawa, A., Painter, J., Hess, K., and Colen, R. (2017). Efficacy of pembrolizumab in patients with cutaneous aquamous cell carcinoma. J. Immunother. Cancer, 5."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e21015","DOI":"10.1200\/JCO.2019.37.15_suppl.e21015","article-title":"Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma: An updated analysis","volume":"37","author":"Yushak","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.19.03357","article-title":"Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas","volume":"38","author":"Maubec","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e15100","DOI":"10.1200\/JCO.2018.36.15_suppl.e15100","article-title":"PD-1 inhibition in cutaneous squamous cell carcinoma (cSCC)","volume":"36","author":"Hermel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1684\/ejd.2019.3671","article-title":"Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma","volume":"29","author":"Lavaud","year":"2019","journal-title":"Eur. J. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor Regression and Allograft Rejection after Administration of Anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1111\/ajt.15856","article-title":"Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection","volume":"20","author":"Lipson","year":"2020","journal-title":"Am. J. Transpl."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clsc.2016.11.001","article-title":"Unresectable cutaneous squamous cell carcinoma of the forehead with MLH1 mutation showing dramatic response to Programmed Cell Death Protein 1 Inhibitor Therapy","volume":"1","author":"Assam","year":"2016","journal-title":"Clin. Skin. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamadermatol.2015.2705","article-title":"A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor","volume":"152","author":"Chang","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamadermatol.2016.3884","article-title":"Follow-up on programmed cell death 1 inhibitor for cutaneous squamous cell carcinoma","volume":"153","author":"Tran","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2017.06.022","article-title":"Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature","volume":"83","author":"Deinlein","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jamadermatol.2016.5118","article-title":"Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab","volume":"153","author":"Stevenson","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1111\/jdv.14371","article-title":"Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma","volume":"32","author":"Degache","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Steineck, A., Krumm, N., Sarthy, J.F., Pritchard, C.C., Chapman, T., Stacey, A.W., Vitanza, N.A., and Cole, B. (2019). Response to Pembrolizumab in a Patient with Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma. JCO Precis. Oncol., 3.","DOI":"10.1200\/PO.19.00028"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Ma, W.L., Chou, C.H., Chen, J.P., and Kuo, S.H. (2020). Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2. Dermatol. Ther., e14035.","DOI":"10.1111\/dth.14035"},{"key":"ref_80","first-page":"e8072","article-title":"Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab","volume":"12","author":"Cristancho","year":"2020","journal-title":"Cureus"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.annder.2019.10.031","article-title":"Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab","volume":"147","author":"Delaitre","year":"2020","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s40425-019-0801-z","article-title":"Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sezary syndrome","volume":"7","author":"Khaddour","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Rischin, D., Migden, M.R., Lim, A.M., Schmults, C.D., Khushalani, N.I., Hughes, B.G.M., Schadendorf, D., Dunn, L.A., Hernandez-Aya, L., and Chang, A.L.S. (2020). Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2020-000775"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Escobar, G.F., Granel-Brocard, F., Schmutz, J.L., Cervantes, P., Ben Mahmoud, S., and Bursztejn, A.C. (2020). Simultaneous response of cutaneous and lung squamous cell carcinoma with cemiplimab. Dermatol. Ther., e13951.","DOI":"10.1111\/dth.13951"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): Evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jdcr.2017.06.005","article-title":"Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade","volume":"3","author":"Miller","year":"2017","journal-title":"JAAD Case Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e000908","DOI":"10.1136\/jitc-2020-000908","article-title":"Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients","volume":"8","author":"Trager","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-14-1768","article-title":"Mutational landscape of aggressive cutaneous squamous cell carcinoma","volume":"20","author":"Pickering","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00262-018-2138-8","article-title":"PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma","volume":"67","author":"Varki","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/cup.12728","article-title":"PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis","volume":"43","author":"Slater","year":"2016","journal-title":"J. Cutan. Pathol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/DAD.0000000000001164","article-title":"PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases","volume":"40","author":"Andrades","year":"2018","journal-title":"Am. J. Dermatopathol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/cup.13709","article-title":"PD-L1 and LAG-3 expression in advanced cutaneous squamous cell carcinomas","volume":"47","author":"Wu","year":"2020","journal-title":"J. Cutan Pathol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-67577-0_2","article-title":"Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment","volume":"1036","author":"Gajewski","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: First Global Approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"ref_109","unstructured":"U.S. Food and Drug Administration (2020, October 22). FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-cutaneous-squamous-cell-carcinoma."},{"key":"ref_110","unstructured":"European Medicines Agency (EMA) (2020, October 28). Libtayo (Cemiplimab). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/libtayo."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jdv.15846","article-title":"Comparison of guidelines for the management of patients with high-risk and advanced cutaneous squamous cell carcinoma\u2014A systematic review","volume":"33","author":"Heppt","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_112","unstructured":"Global Observatory on Donation and Transplantation (2020, June 09). Summary\u2014Total Number of Organ Transplant Recipients in Germany and Global. Available online: http:\/\/www.transplant-observatory.org\/summary\/."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/bjd.15931","article-title":"Epidemiology of keratinocyte carcinomas after organ transplantation","volume":"177","author":"Madeleine","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/bjd.15956","article-title":"The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients","volume":"177","author":"Harwood","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_115","unstructured":"Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft, Deutsche Krebshilfe, and AWMF (2020, June 05). S3-Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut, Langversion 1.1. Available online: https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/aktinische-keratosen-und-plattenepithelkarzinom-der-haut\/."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrm3822","article-title":"Understanding nucleotide excision repair and its roles in cancer and ageing","volume":"15","author":"Marteijn","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_117","first-page":"1159","article-title":"Xeroderma Pigmentosum\u2014Facts and Perspectives","volume":"38","author":"Lehmann","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejca.2017.02.026","article-title":"Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab","volume":"77","author":"Hauschild","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/bjd.16270","article-title":"Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum","volume":"178","author":"Salomon","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Chambon, F., Osdoit, S., Bagny, K., Moro, A., Nguyen, J., and Reguerre, Y. (2018). Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. Pediatr. Blood Cancer, 65.","DOI":"10.1002\/pbc.26837"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.16525","article-title":"Pembrolizumab treatment of a patient with xeroderma pigmentosum with disseminated melanoma and multiple nonmelanoma skin cancers","volume":"178","author":"Kraemer","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/1872213X10666160504104825","article-title":"Actinic Keratosis Pathogenesis Update and New Patents","volume":"10","author":"Cantisani","year":"2016","journal-title":"Recent Pat. Inflamm. Allergy Drug Discov."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e14540","DOI":"10.1200\/JCO.2016.34.15_suppl.e14540","article-title":"Resolution of pre-cancerous and non-melanoma skin cancers after immune checkpoint inhibitor treatments","volume":"34","author":"Orloff","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e000897","DOI":"10.1136\/jitc-2020-000897","article-title":"Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: A retrospective multicenter DeCOG study of 84 patients","volume":"8","author":"Leiter","year":"2020","journal-title":"J. Immunother. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/23\/9300\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:41:36Z","timestamp":1760179296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/23\/9300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,6]]},"references-count":124,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["ijms21239300"],"URL":"https:\/\/doi.org\/10.3390\/ijms21239300","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,6]]}}}